Aryan Poduri's book, "GOAT Coder," teaches children how to code through hands-on exercises and uncomplicated explanations.

OpenAI alum Andrej Karpathy wrote on X that his failure to fully claim the 10x boost of new tools felt like a "skill issue." ...

Aider is a “pair-programming” tool that can use various providers as the AI back end, including a locally running instance of ...

Even as they build out agentic tools themselves, leaders from the two companies say the capabilities aren’t quite there yet.

The rise of artificial intelligence has produced serial writers to science and medical journals, most likely using chatbots to boost the number of citations they’ve published. By Gina Kolata Letters ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

James Craig and Louis Giles’ new film “Code Is Law” examines infamous crypto hacks and the moral reckoning used by the perpetrators. “A world where ‘the market’ runs free and the ‘evil’ of government ...

Amazon introduced a Nova Act extension to build and test AI agents directly inside integrated development environments including Visual Studio Code, Amazon’s Kiro, and Cursor. The company says the new ...

Artificial intelligence code review startup CodeRabbit Inc. has raised $60 million in a Series B funding, a round that it says demonstrates its growing importance at a time when AI-generated code is ...

A weakness in the Cursor code editor exposes developers to the risk of automatically executing tasks in a malicious repository as soon as it’s opened. Threat actors can exploit the flaw to drop ...

Cybersecurity researchers have disclosed a high-severity security flaw in the artificial intelligence (AI)-powered code editor Cursor that could result in remote code execution. The vulnerability, ...

Replimune (NASDAQ:REPL) climbed more than 100% on Wednesday as Cantor Fitzgerald upgraded the cancer drug developer, citing a potential reversal of an FDA decision that rejected its lead drug ...